Bayer : Hopes rest on the announcement of a new corporate structure in March 2024 - little positive impetus expected from earnings development
>A strong Q4 is needed to meet the lower end of the 2023 guidance - Q3 2023 results provided a mixed picture with Pharma beating earnings estimates, whereas Consumer Health and Crop Science disappointed as the latter posted even an adj. EBITDA in negative territory. Hence, after nine months it appears extremely challenging to meet the mid-point of the company’s guidance but even the lower end of the group’s adjusted EDITDA guidance (€ 11.3bn) needs a strong Q4 with ad...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.